ENMD-2076 tartrate - CAS# 1291074-87-7 lol metabolite 4-Hydroxyphenyl Carvedilol InChi: InChI=1S/C33H35F3N6O3/c1-19(2)15-16-37-31(44)21-8-14-28-27(18-21)38-32(42(28)22-9-11-23(43)12-10-22)39-30-25-17-20(7-13-26(25)40-41-30)24-5-3-4-6-29(24)45-33(34

InChi: InChI=1S/C33H35F3N6O3/c1-19(2)15-16-37-31(44)21-8-14-28-27(18-21)38-32(42(28)22-9-11-23(43)12-10-22)39-30-25-17-20(7-13-26(25)40-41-30)24-5-3-4-6-29(24)45-33(34

Mestranol significantly increases the non-focal hepatic labeling index in uninitiated rats compared with that observed in rats administered the basal diet only

PMID: 31927622

Characterization of EHT 1864

ENMD-2076 tartrate - CAS# 1291074-87-7 lol metabolite 4-Hydroxyphenyl Carvedilol InChi: InChI=1S/C33H35F3N6O3/c1-19(2)15-16-37-31(44)21-8-14-28-27(18-21)38-32(42(28)22-9-11-23(43)12-10-22)39-30-25-17-20(7-13-26(25)40-41-30)24-5-3-4-6-29(24)45-33(34ENMD 2076 is an orally active, Aurora A angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD 2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over expressed in human cancers. ENMD 2076 also targets the VEGFR, Flt 3 and FGFR3 kinases which have been